目的：探讨家庭雾化吸入糖皮质激素(ICS)布地奈德与口服孟鲁司特钠治疗哮喘预测指数阳性的婴幼儿喘息的临床效果。方法将2013年6月~2014年6月在我院儿科门诊哮喘预测指数阳性的婴幼儿喘息患儿90例随机分为ICS组和孟鲁司特钠组，每组45例。两组均在急性喘息发作期给予综合治疗。缓解期ICS组给予家庭雾化治疗，每天通过压缩式雾化器吸入布地奈德混悬液，每1~3个月调整一次用药方案，剂量从1 mg/d逐渐减量至0.25 mg/d。孟鲁司特钠组口服孟鲁司特钠治疗，剂量为4 mg/d，1次/d。两组疗程均为6个月，期间观察临床疗效及不良事件发生情况。结果 ICS组临床缓解率高于孟鲁司特钠组，差异有统计学意义(P<0.05)；ICS组复发率低于孟鲁司特钠组，差异有统计学意义(P<0.05)。用药期间未见明显不良反应。结论应用家庭雾化吸入布地奈德治疗哮喘预测指数阳性的婴幼儿喘息优于孟鲁司特钠，安全性好，值得推广。%Objective To compare the clinical effect of two therapeutic methods including budesonide as an inhaled corticosteroid (ICS) by family atomization and montelukast sodium (MS) in oral administration on treating infant panting with positive asthma predictive index. Methods From June 2013 to June 2014,90 patients with asthma in our hospital were randomly divided into ICS group and MS group in random.The comprehensive treatment was provided during acute asthmatic attack.In remission,family atomization in ICS group was applied.Budesonide suspension was inhaled by com-pressed atomizer every day and regimen of medication was adjusted every one to three month with dosage decreasing from 1 mg/d to 0.25 mg/d.In MS group,oral administration of MS was adopted and the dosage was 4 mg/d,once per day. The courses of treatment lasted for 6 months.The clinical effect and occurrence of adverse incidences were observed. Results The clinical remission rate in ICS group was higher than that in MS group,with a statistical difference(P<0.05). In the ICS group,the recurrence rate was lower in comparison with that in MS group,with a statistical difference (P<0.05).There was no obvious adverse reaction occurred during medication. Conclusion Application of family atomization to treat infant panting with positive asthma predictive index is superior to that by MS.It has a good safety,and is worthy of promotion.
展开▼
